Starling Oncology Past Earnings Performance
Past criteria checks 0/6
Starling Oncology's earnings have been declining at an average annual rate of -31%, while the Healthcare industry saw earnings growing at 11.6% annually. Revenues have been growing at an average rate of 22% per year.
Key information
-31.04%
Earnings growth rate
-22.45%
EPS growth rate
| Healthcare Industry Growth | 8.50% |
| Revenue growth rate | 21.95% |
| Return on equity | n/a |
| Net Margin | -5.20% |
| Last Earnings Update | 30 Jun 2026 |
Recent past performance updates
Recent updates
STLN: Capitated Revenue Outlook To 300M In 2027 Will Support Bullish Repricing
Analysts now frame Starling Oncology with a higher fair value, lifting the price target from $10 to $11. They point to company guidance that capitated revenue could reach $300M in 2027, which they describe as thesis changing for the stock.US$9.00 - That's What Analysts Think Starling Oncology, Inc. (NASDAQ:STLN) Is Worth After These Results
Shareholders will be ecstatic, with their stake up 32% over the past week following Starling Oncology, Inc. 's...
STLN: Capitated Revenue Outlook To 2027 Will Support Higher Forward Earnings Power
Analysts have raised their Starling Oncology price target by $0.65 to $8.40, citing updated expectations for capitated revenue that some describe as "thesis changing" after management guided for revenue to reach $300M in 2027. What’s in the News for Starling Oncology On July 28, 2026, The Oncology Institute, Inc.TOI: Index Additions And 2026 Guidance Will Support Bullish Repricing
Analysts have raised their fair value estimate for Oncology Institute from $8.00 to $10.00, citing revised assumptions for revenue growth, profit margins, the discount rate, and a substantially higher future P/E multiple in their updated price target analysis. What’s in the News for Oncology Institute Oncology Institute was added to the Russell Small Cap Comp Value Benchmark, according to index constituent updates.
TOI: Index Additions And 2026 Guidance Will Support Future Upside Potential
Analysts have raised their fair value estimate for Oncology Institute from $5.00 to $7.00, citing updated assumptions for revenue growth, profit margins, a higher future P/E multiple, and a slightly higher discount rate. What's in the News Oncology Institute was added to the Russell Microcap Value Benchmark Index, according to index constituent change data.TOI: Reaffirmed 2026 Revenue Outlook Will Support Higher Forward Earnings Power
Analysts have raised their price target for Oncology Institute to $7.75 from $7.00, citing updated assumptions for revenue growth, profit margins, and a lower future P/E multiple in their valuation work. What’s in the News for Oncology Institute Oncology Institute reaffirmed earnings guidance for fiscal 2026, keeping anticipated total revenue in the range of $630 million to $650 million.The Oncology Institute, Inc. (NASDAQ:TOI) Analysts Are Pretty Bullish On The Stock After Recent Results
As you might know, The Oncology Institute, Inc. ( NASDAQ:TOI ) just kicked off its latest first-quarter results with...Investors Give The Oncology Institute, Inc. (NASDAQ:TOI) Shares A 26% Hiding
Unfortunately for some shareholders, the The Oncology Institute, Inc. ( NASDAQ:TOI ) share price has dived 26% in the...The Oncology Institute: Making Progress
Summary The Oncology Institute recently achieved its first profitable Adj. EBITDA for the month and posted 37% YoY revenue growth, beating consensus by $13.9M. TOI raised FY25 guidance to $500M revenue and expects positive Adj. EBITDA in Q4, with cash flow positivity likely by mid-2026. Despite a massive share price surge in 12 months, GAAP EPS profitability remains two years away; consolidation is expected before a favorable entry point. An analysis of The Oncology Institute follows in the paragraphs below. Read the full article on Seeking AlphaInvestors Give The Oncology Institute, Inc. (NASDAQ:TOI) Shares A 29% Hiding
The Oncology Institute, Inc. ( NASDAQ:TOI ) shareholders won't be pleased to see that the share price has had a very...Market Cool On The Oncology Institute, Inc.'s (NASDAQ:TOI) Revenues Pushing Shares 26% Lower
The Oncology Institute, Inc. ( NASDAQ:TOI ) shares have retraced a considerable 26% in the last month, reversing a fair...The Oncology Institute, Inc. (NASDAQ:TOI) Stock Rockets 30% But Many Are Still Ignoring The Company
The Oncology Institute, Inc. ( NASDAQ:TOI ) shares have continued their recent momentum with a 30% gain in the last...Value Based Care Contracts Will Unlock Future Oncology Demand
New value-based care contracts and expanded partnerships are driving sustained growth and enhancing recurring revenue in a shifting oncology market.A Piece Of The Puzzle Missing From The Oncology Institute, Inc.'s (NASDAQ:TOI) 161% Share Price Climb
The Oncology Institute, Inc. ( NASDAQ:TOI ) shares have continued their recent momentum with a 161% gain in the last...Market Cool On The Oncology Institute, Inc.'s (NASDAQ:TOI) Revenues Pushing Shares 28% Lower
The Oncology Institute, Inc. ( NASDAQ:TOI ) shares have retraced a considerable 28% in the last month, reversing a fair...The Oncology Institute, Inc. (NASDAQ:TOI) Stock Rockets 195% But Many Are Still Ignoring The Company
The Oncology Institute, Inc. ( NASDAQ:TOI ) shareholders would be excited to see that the share price has had a great...A Piece Of The Puzzle Missing From The Oncology Institute, Inc.'s (NASDAQ:TOI) 28% Share Price Climb
The Oncology Institute, Inc. ( NASDAQ:TOI ) shareholders are no doubt pleased to see that the share price has bounced...The Oncology Institute, Inc. (NASDAQ:TOI) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Unfortunately for some shareholders, the The Oncology Institute, Inc. ( NASDAQ:TOI ) share price has dived 29% in the...Revenue & Expenses Breakdown
How Starling Oncology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 26 | 587 | -31 | 111 | 0 |
| 31 Mar 26 | 546 | -36 | 108 | 0 |
| 31 Dec 25 | 503 | -50 | 106 | 0 |
| 30 Sep 25 | 461 | -55 | 102 | 0 |
| 30 Jun 25 | 424 | -54 | 104 | 0 |
| 31 Mar 25 | 403 | -53 | 105 | 0 |
| 31 Dec 24 | 393 | -53 | 108 | 0 |
| 30 Sep 24 | 379 | -57 | 111 | 0 |
| 30 Jun 24 | 361 | -59 | 113 | 0 |
| 31 Mar 24 | 343 | -60 | 113 | 0 |
| 31 Dec 23 | 324 | -68 | 114 | 0 |
| 30 Sep 23 | 310 | -61 | 116 | 0 |
| 30 Jun 23 | 293 | -50 | 120 | 0 |
| 31 Mar 23 | 274 | -40 | 120 | 0 |
| 31 Dec 22 | 252 | 0 | 120 | 0 |
| 30 Sep 22 | 233 | -1 | 137 | 0 |
| 30 Jun 22 | 221 | -2 | 118 | 0 |
| 31 Mar 22 | 210 | 6 | 100 | 0 |
| 31 Dec 21 | 203 | -11 | 83 | 0 |
| 30 Sep 21 | 200 | -6 | 50 | 0 |
| 30 Jun 21 | 195 | -3 | 46 | 0 |
| 31 Mar 21 | 192 | -5 | 44 | 0 |
| 31 Dec 20 | 188 | -14 | 42 | 0 |
| 31 Dec 19 | 155 | -4 | 30 | 0 |
| 31 Dec 18 | 113 | -2 | 17 | 0 |
Quality Earnings: STLN is currently unprofitable.
Growing Profit Margin: STLN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: STLN is unprofitable, and losses have increased over the past 5 years at a rate of 31% per year.
Accelerating Growth: Unable to compare STLN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: STLN is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (20.8%).
Return on Equity
High ROE: STLN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/23 11:09 |
| End of Day Share Price | 2026/08/21 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Starling Oncology, Inc. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yuan Zhi | B. Riley Securities, Inc. |
| David Larsen | BTIG |
| Alexander Draper | Guggenheim Securities, LLC |